Literature DB >> 11114714

Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide.

M J Jenner1, I N Micallef, A Z Rohatiner, S M Kelsey, A C Newland, J D Cavenagh.   

Abstract

A 36-year-old man underwent matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia. He developed severe hepatic veno-occlusive disease as an early post-transplant complication. Tissue plasminogen activator was initially felt to be contraindicated since the patient had concomitant pericarditis. Defibrotide was therefore commenced as treatment for veno-occlusive disease. The pericarditis improved but the veno-occlusive disease continued to worsen (peak bilirubin 353 micromol/l). Tissue plasminogen activator followed by a heparin infusion was therefore administered. However, he proceeded to develop haemorrhagic cardiac tamponade that required drainage. Thrombolysis was therefore discontinued and treatment with defibrotide resumed after an interval of 48 h. The veno-occlusive disease gradually resolved and defibrotide was discontinued once the bilirubin had plateaued. He was discharged home on day +52 post-transplant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114714     DOI: 10.1007/bf02782200

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  18 in total

1.  Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial.

Authors:  M Attal; F Huguet; H Rubie; A Huynh; J P Charlet; J L Payen; J J Voigt; P Brousset; J Selves; C Muller
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

Review 2.  Venocclusive disease of the liver after bone marrow transplantation: the role of hemostasis.

Authors:  E M Faioni; P M Mannucci
Journal:  Leuk Lymphoma       Date:  1997-04

3.  Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.

Authors:  J D Morris; R E Harris; R Hashmi; J E Sambrano; R A Gruppo; A T Becker; C L Morris
Journal:  Bone Marrow Transplant       Date:  1997-11       Impact factor: 5.483

4.  Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate.

Authors:  D F Patton; J L Harper; T N Wooldridge; B G Gordon; P Coccia; W D Haire
Journal:  Bone Marrow Transplant       Date:  1996-03       Impact factor: 5.483

5.  Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study.

Authors:  J H Lee; K H Lee; S Kim; J S Lee; W K Kim; C J Park; H S Chi; S H Kim
Journal:  Bone Marrow Transplant       Date:  1998-11       Impact factor: 5.483

6.  The syndrome of hepatic veno-occlusive disease after marrow transplantation.

Authors:  S I Bearman
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

7.  Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial.

Authors:  J H Essell; M T Schroeder; G S Harman; R Halvorson; V Lew; N Callander; M Snyder; S K Lewis; J P Allerton; J M Thompson
Journal:  Ann Intern Med       Date:  1998-06-15       Impact factor: 25.391

8.  A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation.

Authors:  S I Bearman; D D Shen; M S Hinds; H A Hill; G B McDonald
Journal:  Br J Haematol       Date:  1993-08       Impact factor: 6.998

9.  Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.

Authors:  J Rosenthal; L Sender; R Secola; R Killen; M Millerick; L Murphy; M S Cairo
Journal:  Bone Marrow Transplant       Date:  1996-07       Impact factor: 5.483

10.  Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation.

Authors:  S I Bearman; M C Shuhart; M S Hinds; G B McDonald
Journal:  Blood       Date:  1992-11-15       Impact factor: 22.113

View more
  1 in total

Review 1.  Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2012-04-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.